Patents by Inventor James A. Tumlin
James A. Tumlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12377060Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.Type: GrantFiled: June 29, 2023Date of Patent: August 5, 2025Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Publication number: 20240041794Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.Type: ApplicationFiled: August 7, 2023Publication date: February 8, 2024Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Publication number: 20240009144Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.Type: ApplicationFiled: June 29, 2023Publication date: January 11, 2024Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Patent number: 11793773Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.Type: GrantFiled: June 16, 2021Date of Patent: October 24, 2023Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Patent number: 11723882Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.Type: GrantFiled: May 11, 2021Date of Patent: August 15, 2023Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Patent number: 11603345Abstract: The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.Type: GrantFiled: May 12, 2022Date of Patent: March 14, 2023Assignee: Epizon Pharma, Inc.Inventors: Keith E. Drouet, James A. Tumlin, John M. Rudey
-
Patent number: 11529445Abstract: The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.Type: GrantFiled: September 20, 2020Date of Patent: December 20, 2022Assignee: HIBAR Microsciences LLCInventor: James A. Tumlin
-
Publication number: 20220348530Abstract: The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.Type: ApplicationFiled: May 12, 2022Publication date: November 3, 2022Applicant: Epizon Pharma, Inc.Inventors: Keith E. Drouet, James A. Tumlin, John M. Rudey
-
Patent number: 11332427Abstract: The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.Type: GrantFiled: September 18, 2020Date of Patent: May 17, 2022Assignee: Epizon Pharma, Inc.Inventors: Keith E. Drouet, James A. Tumlin, John M. Rudey
-
Publication number: 20210378986Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.Type: ApplicationFiled: May 11, 2021Publication date: December 9, 2021Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Publication number: 20210378987Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.Type: ApplicationFiled: June 16, 2021Publication date: December 9, 2021Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Patent number: 11065212Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.Type: GrantFiled: June 16, 2020Date of Patent: July 20, 2021Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Patent number: 11033515Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.Type: GrantFiled: November 20, 2020Date of Patent: June 15, 2021Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Patent number: 10987320Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.Type: GrantFiled: June 16, 2020Date of Patent: April 27, 2021Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Publication number: 20210093584Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.Type: ApplicationFiled: November 20, 2020Publication date: April 1, 2021Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Publication number: 20210069400Abstract: The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.Type: ApplicationFiled: September 20, 2020Publication date: March 11, 2021Applicant: HIBAR Microsciences LLCInventor: James A. Tumlin
-
Patent number: 10940123Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.Type: GrantFiled: July 31, 2020Date of Patent: March 9, 2021Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Patent number: 10925838Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.Type: GrantFiled: June 16, 2020Date of Patent: February 23, 2021Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
-
Publication number: 20210009494Abstract: The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.Type: ApplicationFiled: September 18, 2020Publication date: January 14, 2021Applicant: Epizon Pharma, Inc.Inventors: Keith E. Drouet, James A. Tumlin, John M. Rudey
-
Patent number: 10874623Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.Type: GrantFiled: March 12, 2020Date of Patent: December 29, 2020Assignee: Epizon Pharma, Inc.Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey